This is a Level 3 matched-cohort study asking whether adipose-derived mesenchymal stem cells loaded in fibrin glue improve arthroscopic rotator cuff repair. 35 patients receiving an intraoperative MSC injection were matched to 35 receiving repair alone. Outcomes were pain, ROM, Constant and UCLA scores, plus MRI retear assessment at minimum 12 months.
About half of repaired rotator cuffs fail to heal structurally regardless of suture technique, which is why the field has turned to biological augmentation. This study shows that adding adipose-derived MSCs in fibrin glue during repair halves the MRI retear rate. That is a real structural signal worth knowing.
The critical teaching point is the disconnect: better healing on MRI did not produce better pain, function, or motion at 28 months. Structural integrity and clinical outcome are related but not interchangeable, and follow-up length matters. Weigh the evidence appropriately. This is Level 3 with only 35 patients per arm, a non-randomized design, and no histology.
Do not treat MSC augmentation as a validated standard. It remains investigational, and the optimal cell dose is still unknown.
This is a Level 3 matched-cohort study asking whether adipose-derived mesenchymal stem cells loaded in fibrin glue improve arthroscopic rotator cuff repair. 35 patients receiving an intraoperative MSC injection were matched to 35 receiving repair alone. Outcomes were pain, ROM, Constant and UCLA scores, plus MRI retear assessment at minimum 12 months.
About half of repaired rotator cuffs fail to heal structurally regardless of suture technique, which is why the field has turned to biological augmentation. This study shows that adding adipose-derived MSCs in fibrin glue during repair halves the MRI retear rate. That is a real structural signal worth knowing.
The critical teaching point is the disconnect: better healing on MRI did not produce better pain, function, or motion at 28 months. Structural integrity and clinical outcome are related but not interchangeable, and follow-up length matters. Weigh the evidence appropriately. This is Level 3 with only 35 patients per arm, a non-randomized design, and no histology.
Do not treat MSC augmentation as a validated standard. It remains investigational, and the optimal cell dose is still unknown.